Govt plans central licensing for all sterile drugs after quality lapses
The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally.
India is set to introduce a central licensing system for all sterile drug products, as the government seeks to strengthen quality control measures following recent quality issues, according to officials. The plan aims to tighten oversight of injectables and other medicines, following the discovery of approximately 240 injection samples that did not meet standard quality requirements during fiscal year 2026.
Priyanka Sharma, a journalist at Mint, provides this news. With a background in journalism, public health, and experience at the National Health Authority, Sharma is well-versed in the intricacies of India's healthcare policies and their impact on the pharmaceutical industry.
Written by urgent.news from Live Mint's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
